Home / Stocks / Gufic Biosciences Ltd.
GUFICBIO

Gufic Biosciences Ltd. Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹431.9

Change

+9.65 (2.29%)

Open

₹422.95

Prev. Close

₹422.25

Day High

₹436.0

Day Low

₹417.55

Volume Analysis

Traded

47,566

Delivered

24,494

Delivery %

51.49%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (1)

  • •Below-average fundamentals quality score (49/100)

Opportunities (0)

No signal for this stock

Threats (0)

No signal for this stock

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹457.86 ₹446.93 ₹439.41 ₹428.48 ₹420.96 ₹410.03 ₹402.51
Fibonacci ₹446.93 ₹439.88 ₹435.53 ₹428.48 ₹421.43 ₹417.08 ₹410.03
Camarilla ₹436.97 ₹435.28 ₹433.59 ₹428.48 ₹430.21 ₹428.52 ₹426.83

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

+26.51%

1 Week

-11.31%

1 Month

+10.89%

3 Months

+0.09%

6 Months

+47.05%

1 Year

+26.05%

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹114.43

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

15.31%

Net margin 7.75% × asset turnover 0.8x × equity multiplier 2.47x

Company Overview

Sector

Healthcare

Market Cap

₹4,415 Cr

P/E (TTM)

55.1

ROE

10.1%

Book Value

₹70.8

Face Value

₹1.0

Source: Screener.in (Consolidated figures) — data as of 17 Nov 2026. Not investment advice.

TopFund Analysis

Gufic Biosciences Ltd. scores weakly on TopFund's composite fundamentals check within the Healthcare sector, at 49/100. The strongest factor is Financial Strength (79/100), while Valuation (11/100) is the weakest area to weigh before deciding. Notably: Below-average fundamentals quality score (49/100).

TopFund Score — Fundamentals Quality

49/100 — Weak

Data confidence: 80/100 (High Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

79

Growth

34

Valuation

11

Cash Flow

23

Corporate Governance

60

Momentum

76

Institutional Ownership

42

Business Quality

56

Risk & Volatility

66

Liquidity

35

From Screener.in

  • −Stock is trading at 6.21 times its book value
  • −Company has a low return on equity of 12.8% over last 3 years.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Audio recording of earnings conference call held on November 16, 2026 uploaded on company website.

Newspaper advertisement of Unaudited Financial Results (Standalone and Consolidated) for the quarter and half year ended September 30, 2026 is attached herewith

Dr. Reeta Shah appointed Additional Independent Director from December 1, 2026, subject to shareholder approval.

Q2 FY26 results approved on Nov 14, 2026; standalone revenue ₹288.4 crore, net profit ₹23.5 crore.

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 215 202 195 203 204 208 205 224 237 231 252 261 288
Expenses + 176 165 161 167 166 174 179 190 199 198 205 214 240
Operating Profit 39 36 34 36 39 34 26 33 38 33 47 47 48
OPM % 18.0% 18.0% 18.0% 18.0% 19.0% 16.0% 13.0% 15.0% 16.0% 14.0% 19.0% 18.0% 17.0%
Other Income + 0 0 1 1 0 2 0 1 2 1 -1 0 1
Interest 4 3 4 5 5 5 8 9 10 8 9 9 10
Depreciation 4 4 4 4 4 5 8 8 8 8 8 8 8
Profit before tax 31 30 27 28 29 26 11 17 23 18 29 30 31
Tax % 25.0% 25.0% 26.0% 26.0% 26.0% 26.0% 27.0% 24.0% 26.0% 30.0% 24.0% 26.0% 25.0%
Net Profit + 23 22 20 21 22 19 8 13 17 12 22 22 23
EPS in Rs 2 2 2 2 2 2 1 1 2 1 2 2 2
Raw PDF — — — — — — — — — — — — —
YoY Sales growth — — — — -5 3 5 10 16 11 23 17 22

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 148 201 245 306 351 379 488 779 691 807 820 944 1,032
Expenses + 134 181 222 267 305 327 404 631 556 657 684 793 857
Operating Profit 14 20 23 39 46 52 84 148 135 150 136 151 175
OPM % 10.0% 10.0% 9.0% 13.0% 13.0% 14.0% 17.0% 19.0% 20.0% 19.0% 17.0% 16.0% 17.0%
Other Income + 1 1 1 4 4 6 4 3 3 0 4 3 1
Interest 4 6 6 9 10 14 14 5 8 17 25 37 38
Depreciation 4 4 4 4 5 14 16 19 22 17 21 31 31
Profit before tax 7 10 14 30 35 30 58 127 107 116 94 87 108
Tax % 36.0% 29.0% 37.0% 45.0% 38.0% 25.0% 23.0% 24.0% 25.0% 26.0% 26.0% 26.0% —
Net Profit + 4 7 9 16 22 23 44 96 80 86 70 64 80
EPS in Rs 1 1 1 2 3 3 6 10 8 9 7 6 8
Dividend Payout % 9.0% 5.0% 4.0% 2.0% 2.0% 2.0% 2.0% 1.0% 1.0% 1.0% 1.0% 2.0% —
Sales growth 22 36 22 25 15 8 29 60 -11 — 2 15 18

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 19 26 30 46 68 120 164 259 338 523 591 655 700
Borrowings + 33 43 57 80 98 126 62 64 334 333 336 405 466
Other Liabilities + 67 75 84 104 106 152 157 188 179 227 232 273 276
Total Liabilities 127 152 178 238 280 408 392 521 861 1,093 1,169 1,342 1,451
Fixed Assets + 25 22 22 23 24 83 100 115 160 159 506 491 480
CWIP 0 0 0 2 10 31 13 41 170 307 22 22 52
Investments 0 0 0 0 0 0 0 0 1 2 2 2 9
Other Assets + 102 130 156 213 245 294 279 365 531 625 640 827 910
Total Assets 127 152 178 238 280 408 392 521 861 1,093 1,169 1,342 1,451
Equity Capital 8 8 8 8 8 10 10 10 10 10 10 10 10

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 (S) Mar 2016 (S) Mar 2017 (S) Mar 2018 (S) Mar 2019 (S) Mar 2020 (S) Mar 2021 (S) Mar 2022 (S) Mar 2023 (S) Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + 11 -4 -4 -5 5 47 87 106 -27 -7 123 45
Cash from Investing Activity + -2 -1 -5 -9 -13 -43 -7 -95 -191 -102 -71 -31
Cash from Financing Activity + -5 5 7 14 8 -4 -79 -6 234 82 -37 32
Net Cash Flow 4 0 -1 1 0 0 2 5 17 -27 15 46
Free Cash Flow 9 -5 -8 -13 -8 7 75 19 -214 -116 52 14
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit 92 -8 2 30 33 110 115 94 1 13 107 38

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 72.51% → 72.5%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Public 25.29% 25.17% 24.89% 24.75% 24.2% 23.79% 23.81% 23.51% 23.3% 23.23% 23.36% 23.66%
Promoters 72.51% 72.51% 72.51% 72.51% 72.51% 72.51% 72.51% 72.5% 72.5% 72.5% 72.5% 72.5%
FII 0.47% 0.12% 0.23% 0.23% 0.3% 0.31% 0.32% 0.33% 0.44% 0.42% 0.47% 0.44%
DII 1.72% 2.2% 2.38% 2.51% 2.99% 3.39% 3.38% 3.66% 3.74% 3.83% 3.67% 3.38%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Gufic Biosciences Ltd. (this stock) 4,415 55.1 6.21 10.1%
Kwality Pharmaceuticals L 4,370 45.3 11.31 22.6%
Zota Health Care Limited 4,492 — 7.17 -15.0%
Aarti Drugs Ltd. 4,589 19.9 2.73 13.4%
Rpg Life Sciences Ltd 4,220 36.8 6.13 19.3%
Gujarat Themis Biosyn Ltd 4,659 239.0 4.55 16.2%
Sms Pharmaceuticals Ltd. 4,758 40.7 5.64 14.3%

Which Mutual Funds Hold Gufic Biosciences Ltd.?

Frequently Asked Questions about Gufic Biosciences Ltd.

Community Sentiment

What are other investors saying about Gufic Biosciences Ltd.?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.